ABVC BioPharma Provides Vitargus® Update
August 26, 2021 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Aug. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Reports Second Quarter 2021 Results
August 12, 2021 08:27 ET
|
ABVC BioPharma, Inc.
Clinical Trials Continue Despite COVID-19 Restrictions Fremont, CA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc., a clinical stage biopharmaceutical company...
ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering
August 03, 2021 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...
American BriVision Issues Shareholder Letter Outlining Achievements of 2020 and Outlook for 2021
January 06, 2021 09:00 ET
|
American BriVision Holding Corporation
FREMONT, CA, Jan. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic...
American BriVision Issues Clinical Study Report for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
November 09, 2020 09:00 ET
|
American BriVision Holding Corporation
· PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) · Phase II Part I...
American BriVision Issues Clinical Study Report for Vitargus First-in-Human Phase I Clinical Trial
September 09, 2020 09:00 ET
|
American BriVision Holding Corporation
FREMONT, CA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic...
American BriVision Announces New Patent Filed for Treatment of Major Depressive Disorder
August 24, 2020 09:00 ET
|
American BriVision Holding Corporation
FREMONT, CA, Aug. 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical-stage biopharmaceutical company developing...
American BriVision Reports Completion of ABV-1505 Phase II Part I Clinical Trial for Treatment of Adult ADHD
July 28, 2020 09:00 ET
|
American BriVision Holding Corporation
· Last patient last visit (LPLV) marked the final step toward the completion of ABV-1505 Phase II Part I clinical trial in treatment of adult attention-deficit hyperactivity disorder (ADHD). ...
American BriVision Announces Completed Patient Enrollment in Clinical Trial at UCSF for Treatment of Adult ADHD
June 15, 2020 09:00 ET
|
American BriVision Holding Corporation
Patient enrollment has been completed for a Phase II Part I clinical trial at the University of California, San Francisco (UCSF) Medical Center Primary objective of Phase II Part I clinical trial is...
American BriVision Increases Size of Private Placement to Raise $2 Million
May 21, 2020 09:00 ET
|
American BriVision Holding Corporation
FREMONT, CA, May 21, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions...